Psychedelics for Vets: Trump Signs Order to Speed Care

Trump Pushes Psychedelic Therapy for Veterans

President Trump signed executive orders aimed at speeding up access to new medical treatments, especially those involving psychedelic drugs. He announced this historic move on April 18th, highlighting its importance for people suffering from severe mental illness, depression, and particularly for veterans. Many of these experimental treatments have shown promise in changing lives.

The President mentioned that he was inspired to act after hearing from people like Joe Rogan. He felt that waiting years for these treatments to become available was too long.

The order directs the FDA to speed up its review of certain psychedelic drugs that have already been designated as “breakthrough therapy” drugs. This designation means early research shows they could be significantly better than existing treatments.

Addressing the Veteran Suicide Crisis

A major focus of the executive order is the crisis of veteran suicide. The transcript states that since 9/11, over 21 times more veteran lives have been lost to suicide than on the battlefield.

This statistic highlights the urgent need for new solutions. The President expressed hope that these new treatments will lead to a significant reduction in this tragic number.

Several key figures were present to support the initiative, including Secretary of Health and Human Services Robert F. Kennedy Jr., FDA Commissioner Dr. Marty McCary, CMS Administrator Dr. Meett Oz, and NIH Director Dr. Jay Bacheria.

Also in attendance were Congressman Morgan Latrell and retired Navy SEAL Marcus Latrell, who have personal experience with the challenges faced by veterans. Joe Rogan was also acknowledged for helping bring national attention to these treatments.

Expediting Drug Review and ‘Right to Try’

The executive order aims to clear unnecessary bureaucratic hurdles and improve data sharing between the FDA and the Department of Veterans Affairs. It will also help speed up the rescheduling of psychedelic drugs once they are approved by the FDA. This process is expected to move much faster than traditional drug approvals.

The President also highlighted his administration’s efforts to lower drug costs. He mentioned a policy that has already reduced drug prices significantly, sometimes by 50-70%. He contrasted this with previous years when drug prices consistently rose.

The transcript also references the “Right to Try” law, which the President initiated. This law allows terminally ill patients to access experimental drugs that have not yet received full FDA approval, under medical supervision.

Early Research and Promising Results

Research into treatments like Ibo gain is already showing strong results. A 2024 study from Stanford University showed that 30 special operations veterans with traumatic brain injuries experienced an 80-90% reduction in symptoms of depression and anxiety within one month of Ibo gain treatment. This led to a $50 million federal research investment, matching a similar commitment from Texas Republican leaders.

The order also opens a pathway for Ibo gain to be administered to patients under the “Right to Try” law. This is seen as a critical step for those with treatment-resistant conditions who have not found relief from existing therapies. The goal is to provide a science-based pathway for FDA approval and controlled medical use, moving beyond just symptom management.

A New Frontier in Mental Health Treatment

Secretary Kennedy emphasized that this move confronts one of the nation’s most urgent public health challenges: the mental health crisis. With millions of Americans suffering from serious mental illness and rising suicide rates, new approaches are desperately needed. He noted that many veterans are currently traveling to other countries to seek treatments like psychedelics, which hold great promise.

The FDA is also announcing new priority vouchers for certain psychedelic compounds, allowing for potential approval in weeks rather than months or years if they align with national priorities. This accelerated pathway is designed to address an unmet public health need. The FDA is also clearing the way for the first human trials in the United States for Ibo gain, with strict criteria for its administration in controlled settings due to potential side effects.

Personal Testimonials and Future Outlook

Marcus Latrell, a retired Navy SEAL, shared his personal experience, stating that Ibo gain treatment changed his life for the better five years ago, allowing him to live his best days every day. He believes this will help both veterans and the civilian population. Joe Rogan spoke about how conversations on his podcast brought national attention to these life-changing treatments.

Brian Huard, who was instrumental in bringing these issues to light, declared that federal prohibition of psychedelic medicine is ending. He thanked President Trump for his courage.

The hope is that these therapies will offer longer-lasting relief and reduce the immense economic burden of mental illness. The commitment is to continue studying these treatments rigorously to ensure safe and effective use.

Source: REPLAY: Trump Signs Executive Orders at White House (April 18) (YouTube)